Physician profile
Amit Arora
NPI 1750598660
$22,165.72
in general payments reported to CMS, 2019-2025
72 companies · $4,171 in 2025
The $4,171 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,338 · 2020: $1,614 · 2021: $2,604 · 2022: $2,978 · 2023: $3,673 · 2024: $4,787 · 2025: $4,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,418.16 |
| Education | $213.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,120.28 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Abbvie INC. | $2,294.53 | 2019-2025 | Botox, Qulipta, Ubrelvy |
| Pfizer INC. | $1,545.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,318.97 | 2019-2025 | |
| Genentech USA, INC. | $737.27 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Argenx US, INC. | $728.42 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $714.66 | 2019-2025 | Uplizna |
| Mdd US Operations, LLC | $695.16 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Acadia Pharmaceuticals INC | $683.16 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $593.17 | 2022-2025 | Ingrezza, Ongentys |
| Acorda Therapeutics, INC | $546.85 | 2019-2024 | Inbrija |
| Teva Pharmaceuticals USA, INC. | $546.80 | 2019-2025 | Austedo Xr, Ajovy |
| Alexion Pharmaceuticals, INC. | $539.81 | 2019-2025 | Ultomiris, Soliris |
| Lundbeck LLC | $523.20 | 2019-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $494.10 | 2021-2025 |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.